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Supplementary Table 1c The distribution of germline variants across 2,728 TCGA samples.
TCGA Ovarian counts were collected from the previous report. Supplementary Table 2 Somatic mutations in 2,241 TCGA tumor samples included in the study. Somatic mutation data are unavailable for a subset of samples. Supplementary Table 3a Somatic mutations in 3,355 TCGA tumor samples from 12 cancer types used for identifying recurrent mutations. Supplementary Table 3b Recurrent somatic mutations from 12 TCGA cancer types used for hotspot analysis. Supplementary Table 4 556 cancer-associated genes used in this study.
Supplementary Table 5a 77 blood-specific events detected in 2,728 cases using our standard discovery pipeline. Supplementary Table 5b Low-level blood-specific events detected in DNMT3A, JAK2, SF3B1, GNAS, and IDH2 in TCGA samples. Supplementary Table 5c Deep-sequencing based validation of low-level blood-specific events detected in DNMT3A, JAK2, and SF3B1 in TCGA samples. Supplementary Table 6 Truncation and hotspot variants in four prominent genes (DNMT3A, TET2, JAK2, and ASXL1) involved in HSPC clonal expansion in 6,503 ESP samples. Supplementary Table 7 Rare truncation variants and known hotspot variants detected in DNMT3A, TET2, ASXL1, GNAS, JAK2, SF3B1, IDH1, and IDH2 in 557 WHISP samples. Supplementary Table 8 Exome capture sequencing coverage for 11 TCGA cancer types analyzed. 
